Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics
Drug Development Research · 2025-12 · 86 (8)
DOI: 10.1002/ddr.70197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 21.11.2025. Verfasst von Shayan Asadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran. Hauptthemen laut MEDLINE: Lysosomes, Proteolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 135 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Targeted protein degradation (TPD) is an emerging drug discovery approach aimed at enabling the selective removal of disease‐associated proteins. While proteolysis‐targeting chimeras (PROTACs) have advanced intracellular degradation via the ubiquitin–proteasome system, their limitation to cytosolic proteins excludes ~40% of the human proteome that is extracellular or membrane‐bound. Lysosome‐targeting chimeras (LYTACs) address this gap by harnessing lysosomal trafficking receptors, thereby mediating the degradation of extracellular and membrane proteins. More recently, methylarginine‐targeting chimeras (MrTACs) have extended lysosomal strategies to certain intracellular targets, bypassing proteasomal dependence. This review critically examines the mechanistic underpinnings, design strategies, and bioanalytical challenges associated with lysosome‐mediated degradation platforms. Emphasis is placed on their therapeutic implications, analytical evaluation, and potential for expanding druggable targets. Together, these emerging lysosomal chimeras offer a paradigm shift in TPD, with far‐reaching applications in precision medicine and chemical biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran.
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
- Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Shayan Asadi, Prashant Kesharwani, Amirhossein Sahebkar
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Asadi, S., Taheri-Torbati, M., Kesharwani, P., & Sahebkar, A. (2025). Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics. Drug Development Research, 86(8). https://doi.org/10.1002/ddr.70197
Vancouver
Asadi S, Taheri-Torbati M, Kesharwani P, Sahebkar A. Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics. Drug Development Research. 2025;86(8). doi:10.1002/ddr.70197
BibTeX
@article{Asadi2025,
author = {Asadi, Shayan and Taheri-Torbati, Mina and Kesharwani, Prashant and Sahebkar, Amirhossein},
title = {Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics},
journal = {Drug Development Research},
year = {2025},
volume = {86},
number = {8},
doi = {10.1002/ddr.70197}
}
EUVIMED